Sure, it's a retrospective study, but then the authors aren't trying to submit it to the FDA as adequate evidence of efficacy for treatment of children under 12. Which is exactly what Mesoblast has been attempting for the past 3 or 4 years. And the Silviu fan club are fond of saying well what about long term survival as proof of efficacy? In that study two year survival with Ruxolutinib was as good or better than Remestemcel, so Mesoblast's claims of superior survival suddenly evaporate along with the claims by posters here that there are "no alternatives". Mesoblast have attempted to cherry pick controls, just as in the Covid-ARDS trial which came unglued in a randomised controlled clinical trial. That's why the FDA want a randomised controlled trial.
- Forums
- ASX - By Stock
- Ann: CEO Presentation to 2023 Annual General Meeting
Sure, it's a retrospective study, but then the authors aren't...
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.03 |
Change
-0.025(2.38%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.06 | $1.06 | $1.02 | $5.734M | 5.571M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 203347 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 125348 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 203347 | 1.020 |
12 | 412127 | 1.015 |
12 | 92894 | 1.010 |
6 | 80671 | 1.005 |
27 | 111616 | 1.000 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 125348 | 6 |
1.035 | 96469 | 8 |
1.040 | 25000 | 2 |
1.045 | 31585 | 4 |
1.050 | 70234 | 5 |
Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.03 |
  |
Change
-0.025 ( 2.94 %) |
|||
Open | High | Low | Volume | ||
$1.06 | $1.06 | $1.02 | 953870 | ||
Last updated 15.59pm 16/05/2024 ? |
Featured News
MSB (ASX) Chart |